Medi-Tate is an Israeli medical device company. Our company is dedicated to improve men’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). 

The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and FDA cleared for use in the USA.

iTind: BPH Treatment Has Never Been Simpler

iTind is a clinically-proven treatment that relieves lower urinary tract symptoms due to an enlarged prostate, or BPH. The iTind procedure reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant. The treatment is straightforward, does not require overnight hospitalization, and has none of the side effects associated with prescription medication. It has also been shown in initial studies to avoid complications typically associated with major surgery. Developed to meet the needs of active patients, the passive 5 to 7-day treatment period helps minimize downtime and does not compromise sexual function.

Why iTind:

Rapid symptom relief in the majority of patients
Preserves sexual function
Straightforward, outpatient procedure
Temporary implant removed after 5 to 7 days
Minimal downtime
No need for a catheter
Durable results as demonstrated in clinical studies out to 3 years

iTind

Org chart

Teams

Offices